<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171650</url>
  </required_header>
  <id_info>
    <org_study_id>1200.17</org_study_id>
    <nct_id>NCT02171650</nct_id>
  </id_info>
  <brief_title>BIBW 2992 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open-label Extension Study of 1200.1 and 1200.2 of Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective was to collect safety data for BIBW 2992.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events, according to Common Terminology Criteria (CTC) version 3, with particular scrutiny of events that were considered to be dose-limiting toxicities and those that were serious or significant</measure>
    <time_frame>up to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of non-progression as measured by tumor assessment according to Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>every 8 weeks up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients who have completed the prescribed courses of the 1200.1 or&#xD;
             1200.2 studies without clinical disease progression&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Life expectancy of at least three (3) months&#xD;
&#xD;
          -  Written informed consent that is consistent with International Conference on&#xD;
             Harmonization - Good Clinical Practice guidelines&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2&#xD;
&#xD;
          -  Patients must be recovered from previous surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infectious disease&#xD;
&#xD;
          -  Gastrointestinal disorders that may interfere with the absorption of the study drug or&#xD;
             chronic diarrhea&#xD;
&#xD;
          -  Serious illness or concomitant non-oncological disease considered by the investigator&#xD;
             to be incompatible with the protocol&#xD;
&#xD;
          -  Patients with untreated or symptomatic brain metastases. Patients with treated,&#xD;
             asymptomatic brain metastases are eligible if there has been no change in brain&#xD;
             disease status for at least eight (8) weeks, no history of cerebral edema or bleeding&#xD;
             in the past eight (8) weeks and no requirement for steroids or anti-epileptic therapy&#xD;
&#xD;
          -  Cardiac left ventricular function with resting ejection fraction &gt;= CTC Grade 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) less than 1500 / mm3&#xD;
&#xD;
          -  Platelet count less than 100 000 / mm3&#xD;
&#xD;
          -  Bilirubin greater than 1.5 mg / dl (&gt; 26 μmol / L, Systeme International (SI) unit&#xD;
             equivalent)&#xD;
&#xD;
          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than&#xD;
             three times the upper limit of normal (if related to liver metastases greater than&#xD;
             five times the upper limit of normal)&#xD;
&#xD;
          -  Serum creatinine greater than 1.5 mg / dl (&gt; 132 μmol / L, SI unit equivalent)&#xD;
&#xD;
          -  Women and men who are sexually active and unwilling to use a medically acceptable&#xD;
             method of birth control&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy&#xD;
             or hormone therapy (excluding Luteinizing hormone-releasing hormone agonists, or other&#xD;
             hormones taken for breast cancer, or bisphosphonates), or participation in a clinical&#xD;
             study other than 1200.1 or 1200.2&#xD;
&#xD;
          -  Patients unable to comply with the protocol&#xD;
&#xD;
          -  Active alcohol or drug abuse&#xD;
&#xD;
          -  Patients not recovered from any dose-limiting toxicity&#xD;
&#xD;
        The patients are eligible for re-treatment after the previous course is finished. Patients&#xD;
        will not be eligible if the following conditions are met:&#xD;
&#xD;
          -  Patients with clinical signs of disease progression or if latest X-ray, CT, MRI or US&#xD;
             reveals progressive disease&#xD;
&#xD;
          -  Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course&#xD;
&#xD;
          -  Patients fulfilling any of the Exclusion Criteria listed in Section 3.3 on Day 29 of&#xD;
             the previous course&#xD;
&#xD;
          -  Patient not recovered from any dose-limiting toxicity (DLT) 14 days after the last&#xD;
             administration of BIBW2992 in the previous course. Recovery is defined as return to&#xD;
             baseline condition (Visit 1 of 1200.1 or Visit 1 of 1200.2) or CTC Grade 1, whichever&#xD;
             is higher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1200/1200.17_U07-3059-02.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

